McKay, Rana R <br/><br/>
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.  [electronic resource] 

 -  European urology  Sep 2014 
 - 502-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2014.02.040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Axitinib<br/>Bisphosphonate-Associated Osteonecrosis of the Jaw--etiology<br/>Bone Density Conservation Agents--adverse effects<br/>Bone Neoplasms--drug therapy<br/>Carcinoma, Renal Cell--drug therapy<br/>Diphosphonates--adverse effects<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Hypocalcemia--chemically induced<br/>Imidazoles--therapeutic use<br/>Indazoles--therapeutic use<br/>Indoles--therapeutic use<br/>Interferon-alpha--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Pamidronate<br/>Phenylurea Compounds--therapeutic use<br/>Prognosis<br/>Pyrroles--therapeutic use<br/>Renal Insufficiency--chemically induced<br/>Retrospective Studies<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sunitinib<br/>Survival Rate<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Zoledronic Acid